Results 181 to 190 of about 104,287 (300)

Association between Dupilumab and Ocular Surface Diseases in Children. [PDF]

Ophthalmol Sci
Ayoubi M, Eleiwa TK, Chacko JA, Pemberton JD, Saeed HN, Phillips PH, Elhusseiny AM.   +6 more
europepmc   +1 more source

Inclusion Conjunctivitis [PDF]

British Journal of Ophthalmology, 1942
openaire   +2 more sources

Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real‐world study

International Journal of Cancer, Volume 158, Issue 10, Page 2674-2683, 15 May 2026.
What's new? Mitogen‐activated protein kinase (MAPK) inhibitors are promising treatments for pediatric Langerhans cell histiocytosis (LCH), a rare heterogeneous neoplasm that often affects multiple organ systems. Which MAPK inhibitors are most effective against LCH remains uncertain.
Xue Tang, Jing‐jing Sun, Zhi Wan, Xiao‐yu Jing, Xia Guo, Ju Gao   +5 more
wiley   +1 more source

Ocular manifestations of Clade Ib mpox in four South-Kivu health zones, Democratic Republic of the Congo. [PDF]

PLOS Glob Public Health
Ngoma DB, Ntererwa IN, Irenge AB, Mweze MC, Katoto PMC, Lupande DM, Fodjo JNS, Noë P, Otiti JS, Kabesha TB, Colebunders R, Van Dijck C, Liesenborghs L, Mbala-Kingebeni P, Yeh S, Mwanza JC.   +15 more
europepmc   +1 more source

Relationship Between Knowledge and Compliance With Safety Measures: Evidence From COVID‐19

Applied Economic Perspectives and Policy, Volume 48, Issue 2, Page 487-504, May 2026.
ABSTRACTCompliance with health safety protocols is important for protecting public health, particularly in agricultural sectors where disease outbreaks can disrupt production and market access. Despite its economic significance, we know little about what drives protocol compliance.
Nilufer Cetik, Carola Grebitus, Lauren Chenarides   +2 more
wiley   +1 more source

Evaluation and modulation of bactericidal potential of different antibacterial agents against bacterial pathogens from conjunctivitis infections. [PDF]

J Ophthalmic Inflamm Infect
Arshad S, Ali NM, Munir S, Wasif M, Chaudhry M, Mazhar B, Raza MA.   +6 more
europepmc   +1 more source

Fruquintinib Plus TAS‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a third‐ or later‐line therapy for mCRC.
Yi Wang, Jianfen Xu, Linchun Liang, Yunjie Chen, Leizheng Fei, Jing Hu, Jianjiong Li, Yi Lu, Feng Ren, Ke Chen, Yanping Shen, Qingsong Tao, Zhi Fang, Kaitai Liu, Hua Ye, Jing Zhang, Yunbao Xu, Haoxun Mao, Chen Zhang, Chuangzhou Rao   +19 more
wiley   +1 more source

Investigating tralokinumab-related adverse events in treating atopic dermatitis: insights from the FAERS database. [PDF]

Front Immunol
Jiang Y, Sun X, Li Y.
europepmc   +1 more source

Less Can Be Enough: Sustained Remission of Pediatric Eosinophilic Esophagitis With Low‐Frequency Dupilumab

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Eosinophilic esophagitis (EoE) is a chronic, immune‐mediated disease requiring long‐term therapy. Dupilumab, an interleukin‐4 and interleukin‐13 receptor antagonist, is approved for EoE at a weekly 300 mg dosing regimen. However, data on reduced‐frequency dosing, especially in pediatric patients, remain limited.
Giovanni Scatigna, Annarita Iadecola, Martina Piersanti, Giovanni Di Nardo, Maurizio Mennini   +4 more
wiley   +1 more source

Fungal-specific IgG responses in allergic conjunctivitis: comparison with IgE and immunological implications. [PDF]

PeerJ
Mimura T.
europepmc   +1 more source